Lupin announced it has received tentative approval for its Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL, Unit-dose Vials, from
the United States Food and Drug Administration (U.S. FDA) to market a generic version of Brovana Inhalation Solution, 15 mcg/2 mL of Sunovion Pharmaceuticals Inc. (Sunovion).
Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL, Unit-dose Vials are indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL, Unit-dose Vials (RLD: Brovana) had an annual sales of approximately USD 489 million in the U.S. (IQVIA MAT Feb 2020).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
